USPSTF Recommendation for Overweight, Obese Cost-Effective

Share this content:
USPSTF Recommendation for Overweight, Obese Cost-Effective
USPSTF Recommendation for Overweight, Obese Cost-Effective

MONDAY, Feb. 27, 2017 (HealthDay News) -- Implementing the 2014 U.S. Preventive Services Task Force (USPSTF) recommendations for behavioral counseling is likely to be cost-effective for overweight and obese adults, according to research published online Feb. 17 in Diabetes Care.

Ji Lin, Ph.D., from the U.S. Centers for Disease Control and Prevention in Atlanta, and colleagues examined the long-term cost-effectiveness (CE) of implementing the USPSTF behavioral counselling intervention for overweight or obese adults. A disease progression model was used to simulate the 25-year CE of the recommendation for eligible U.S. adults. Data from systematic reviews were obtained for the cost and effectiveness of the intervention. To assess the CE of the intervention versus no intervention, incremental CE ratios (ICERs), measured in cost/quality-adjusted life-year (QALY), were used.

The researchers estimated that about 98 million U.S. adults would be eligible for the recommended USPSTF intervention. The ICER of the intervention versus no intervention would be $13,900/QALY. There was wide variation in CE among subgroups, ranging from $302 cost saving per capita for obese individuals with impaired fasting glucose, hypertension, and dyslipidemia, to a cost of $103,200/QALY for overweight individuals without those conditions.

"Considerable variation in CE across the recommended subpopulations suggests that prioritization based on risk level would yield larger total health gains per dollar spent," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »